Latest News for Tectonic Metals Stock (OTC:TETOF)

Tectonic Metals Inc is a mineral exploration company engaged, in the identification, acquisition and exploration of mineral properties in the State of Alaska. The company's exploration is focused on discovering and delineating gold resources. Its properties portfolio includes the Tibbs Property; the Seventymile Property; the Maple Leaf property and others.

TECTONIC METALS INC by Tectonic Metals Inc.

Tectonic Metals Inc

SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares are trading higher by 32% to $0.05 during Monday&#8217;s session after the company and Prodways Printers announced they have entered into a technical partnership and ceramic slurry <a href="https://www.benzinga.com/pressreleases/24/04/g38489876/sintx-and-prodways-agree-on-ceramic-slurry-supply-and-3d-printing-agreement">supply agreement</a>.
Under this collaboration, SINTX and its subsidiary will provide ceramic-filled printable slurries to Prodways and aid in process development and customer support. SINTX says this partnership enables comprehensive collaboration in advanced technical ceramics, especially in casting applications.
Ann Kutsch, the General Manager of the SINTX-Maryland site, expressed confidence in their engineering team&#8217;s six-year experience with Prodways printers. They&#8217;ve commercialized various resin compositions and part designs using Prodways equipment. 
Kutsch anticipates that a formal partnership with Prodways will foster breakthrough developments and innovative solutions for their customers.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38488420/broadcom-marvell-set-to-capitalize-on-ai-investments-from-microsoft-alphabet-meta-j">Broadcom, Marvell Set To Capitalize On AI Investments From Microsoft, Alphabet, Meta: JPMorgan</a>
<h2 class="wp-block-heading">How To Buy SINT Stock</h2>
By now you're likely curious about how to participate in the market for SINTX &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href='https://www.benzinga.com/money/best-stock-trading-platforms'>possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of SINTX, which is trading at $0.05 as of publishing time, $100 would buy you 2000.0 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SINT has a 52-week high of $1.82 and a 52-week low of $0.02.

News

SINT

Why SINTX Technologies Shares Are Skyrocketing

Compass Point analyst Casey Alexander maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Neutral and lowers the price target from $490 to $390.

Price Target

Analyst Ratings

KNSL

Compass Point Maintains Neutral on Kinsale Cap Gr, Lowers Price Target to $390

Wedbush analyst David Chiaverini maintains First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) with a Neutral and lowers the price target from $8 to $7.

FFWM

Wedbush Maintains Neutral on First Foundation, Lowers Price Target to $7

Monday,&nbsp;Addex Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38481199/addex-provides-update-on-adx71149-phase-2-epilepsy-study" rel="noreferrer noopener">levetiracetam or brivaracetam</a>.&nbsp;
The company&nbsp;is collaborating&nbsp;with&nbsp;Johnson &amp; Johnson&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;Janssen Pharmaceuticals Inc.
The Phase 2 study did not achieve statistical significance for the primary endpoint&nbsp;of&nbsp;time&nbsp;for&nbsp;patients to reach baseline seizure count when ADX71149 was added to the standard of care.
&#8220;While disappointed that the Phase 2 ADX71149 epilepsy study did not meet the primary endpoint, we are still analyzing the data,&#8221; said Roger Mills,&nbsp;Chief Medical Officer of Addex.&nbsp;
&#8220;We will provide details on data from the full study when this analysis is completed and will work with our partner to determine the next steps for the ADX71149 program,&#8221; Mills added.
The data were reported&nbsp;from a total of 110 evaluable patients, who each received either 50 mg or 100 mg of ADX71149 twice daily (100 mg or 200mg twice daily, respectively, for patients receiving CYP3A4 inducing anti-seizure medication) in addition to their standard dose of levetiracetam or brivaracetam and up to three other anti-seizure drugs.&nbsp;
Adjunctive administration of ADX71149 was safe and well tolerated.
&#8220;While this is disappointing news for us and our partner, Janssen, we remain focused on advancing the rest of our portfolio of allosteric modulator programs toward clinical studies,&#8221; said Tim Dyer, CEO of Addex. &#8220;In particular, we are making great progress in our GABAB PAM collaboration with Indivior, which is on track to select drug candidates for IND enabling studies in June this year for substance use disorder and chronic cough programs.&#8221;
Price Action: ADXN shares are down 50.4% at $7.99 at the last check Monday.
PublicDomainPictures from Pixabay

Biotech

Large Cap

Health Care

Movers

General

ADXN

Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac <a href="https://www.benzinga.com/pressreleases/24/04/g38487200/zyversa-therapeutics-announces-publication-reinforcing-the-rationale-for-inhibiting-asc-with-ic-10">comorbidities in patients with Alzheimer&#8217;s Disease.</a>
The Details:
Researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100, published a scientific paper in the peer-reviewed journal, &#8220;Frontiers in Molecular Neuroscience&#8221;, highlighting how inflammasome-mediated inflammation in Alzheimer&#8217;s disease can trigger inflammation in the heart.
&#8220;This research reinforces the importance of attenuating activation of multiple types of inflammasomes that govern the inflammatory response in AD and mediating systemic inflammatory signals in EVs to control the spread of damaging inflammation to cardiovascular and other cells,&#8221; commented Stephen C. Glover, ZyVersa&#8217;s CEO.&nbsp;
&#8220;ZyVersa&#8217;s Inflammasome ASC inhibitor IC 100 is designed to inhibit formation of multiple types of inflammasomes to attenuate initiation of the inflammatory cascade and to inhibit their associated ASC specks to reduce spread and perpetuation of damaging inflammation,&#8221; Glover added.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ZyVersa effected a reverse stock split with a ratio of 1-for-20 last Friday leaving the stock with a float of less than 758,000 shares.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/04/38469297/whats-going-on-with-immunitybio-stock">What&#8217;s Going On With ImmunityBio Stock?</a>
<h2 class="wp-block-heading">Is ZVSA A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ZVSA">ZyVersa Therapeutics</a>&#8216; page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. ZyVersa Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 9.75%, you'll need to buy a share of Allspring Inc Opps by the May 10. Once done, you can expect to receive a nominal payout of $0.05 on June 3.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href='https://www.benzinga.com/quote/ZVSA'>ZyVersa Therapeutics</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
ZVSA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ZyVersa shares are up 22.5% at $6.11 at the time of publication Monday.
Image: : Phoenix Locklear from Pixabay

Penny Stocks

ZVSA

What's Going On With ZyVersa Stock?

CJS Securities initiates coverage on Thermon Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THR#NYSE">THR</a>) with a Market Outperform rating and announces Price Target of $42.

Initiation

CJS Securities Initiates Coverage On Thermon Group Holdings with Market Outperform Rating, Announces Price Target of $42

Trading Ideas

ANVS

Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -48.1%

Wedbush analyst David Chiaverini maintains Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Neutral and lowers the price target from $9 to $8.

Wedbush Maintains Neutral on Valley Ntl, Lowers Price Target to $8

WIIM

Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.

Canaccord Genuity analyst Jason Tilchen maintains PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Buy and lowers the price target from $32 to $28.

PENN

Canaccord Genuity Maintains Buy on PENN Entertainment, Lowers Price Target to $28

RVTY

Revvity shares are trading higher after the company reported better-than-expected Q1 financial results.

U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for <a href="https://www.benzinga.com/markets/equities/24/04/38485399/tesla-skyrockets-about-10-in-premarket-whats-fueling-the-dramatic-rally">Full Self-Driving in China</a>.
Tesla shares jumped 10.5% to $185.94 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Deciphera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.</li>
<li>Koninklijke Philips N.V.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares gained 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares jumped 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 20.7% to $7.53.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) jumped 20% to $3.38.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) climbed 19% to $1.0250.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) rose 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.</li>
<li>Heartland Financial USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NASDAQ">HTLF</a>) rose 17.2% to $41.86 after UMB Financial announced it will acquire the company.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 14.6% to $50.08.</li>
<li>Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose 14.5% to $4.45.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) jumped 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.</li>
<li>Exscientia plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) rose 12.7% to $4.5399.</li>
<li>Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) gained 11.2% to $4.9182 on FDA clearance of its IND application for PM359.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) climbed 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.</li>
<li>Fulton Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) gained 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.</li>
<li>Tellurian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NYSE">TELL</a>) gained 7.7% to $0.5031.</li>
<li>Medifast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) rose 7% to $36.07.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 6.2% to $1.56.</li>
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) gained 6% to $123.86, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) rose 5.7% to $37.21 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $21 to $45.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) rose 4.8% to $12.48  on reports of the Redstone family and David Ellison making concessions to investors, with Ellison reportedly proposing to purchase a block of shares at a premium.</li>
<li>GrafTech International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NASDAQ">EAF</a>) gained 4.4% to $1.65.        </li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 4.1% to $58.65. Seaport Global analyst David Joyce upgraded Roku from Neutral to Buy and announced a $74 price target.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38489087/jim-cramer-likes-palantir-recommends-pioneer-natural-resources-i-want-you-to-ka-ching-ka-ching">Jim Cramer Likes Palantir, Recommends Pioneer Natural Resources: &#8216;I Want You To Ka-Ching, Ka-Ching&#8217;</a>

Intraday Update

Markets

ALTM

CGEM

DAVE

DCPH

EXAI

FULT

HTLF

IBRX

MESO

MPLN

PACB

PAHC

PARA

PRME

ROKU

SLNO

TELL

TNDM

TSLA

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday

Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -37.8%

Annovis Bio Shares Resume Trading

Canaccord Genuity analyst Maria Ripps maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Hold and lowers the price target from $58 to $50.

Canaccord Genuity Maintains Hold on Zillow Gr, Lowers Price Target to $50

Annovis Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Down -25.6%

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has risen 10.14% since its last report. The company recently reported that it has 3.95 million shares sold short, which is 1.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714401922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 5.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Agilent Technologies?

NNN REIT's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) short percent of float has fallen 9.52% since its last report. The company recently reported that it has 3.54 million shares sold short, which is 2.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>NNN REIT Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714401917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NNN REIT has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing NNN REIT's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, NNN REIT's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NNN) - Analyzing NNN REIT's Short Interest

Marinus Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NYSE">MRNS</a>) short percent of float has fallen 3.64% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 6.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Marinus Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714401912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marinus Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Marinus Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Marinus Pharma's peer group average for short interest as a percentage of float is 3.91%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MRNS

How Is The Market Feeling About Marinus Pharma?

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $65 to $50.

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $50

A Macro Shift At Hand

Tectonic Metals, Inc. (TSE:TECT) has released an update. Tectonic Metals Inc. has enhanced its Board of Directors by appointing the experienced Dr....

Tectonic Metals Welcomes New Board Expertise

AAAU

AAPL

AMZN

ANEW

ARKK

ARKQ

AVGO

BABA

BABAF

BADEF

BBBXF

BGLD

BOTZ

BRKCF

CCOOF

COPX

DTEC

ELRRF

ESKYF

GDMN

GDXD

GDXJ

GDXU

GLDI

GLDM

GLTR

GOAU

GOEX

GOLD

GOOG

GOOGL

GOTRF

IAUF

IAUM

IGLD

IGPT

INTC

IRBO

JJPFF

KOMP

LRNZ

MSFT

NCMGY

NVDA

OUNZ

PALL

PGMFF

PHYS

PICK

PLTM

PPLT

PSLV

REMX

RING

ROBO

ROBT

SESG

SGDJ

SGDM

SGOL

SILJ

SIVR

SLVO

SLVP

SNWGF

TETOF

THNQ

TMUS

UBOT

WAMFF

WTAI

Press Releases

Tectonic Metals Announces Results of Annual General and Special Meeting

OTC Foreign Stocks On The Move Watchlist (SWISF, ACTHF, WRLGF, TETOF)

Offerings

Tectonic Metals Announces Crescat Becoming a Control Person and Closing of Related Tranche

Tectonic Metals Announces Early Exercise Warrant Incentive Program To Boost Funding for Flat Gold Project and On-Trend New Project Opportunities

Penny Stock Momentum Watchlist (ATVK, ILUS, TETOF, NVVE)

Tectonic Metals Acquires Three Additional Potential Intrusions On-Trend with the Flat Gold Project

Tectonic Metals Garners Strong Backing from Warrant Holders and Successfully Concludes Early Exercise Warrant Incentive Program

Tectonic Metals Provides End of Season Update and Site Visit Tour Video for the Flat Gold Project

Tectonic Metals Inaugural 2023 Drilling Intersects Gold Mineralizaiton in Every Drill Hole Extending Mineralization  1.8 KM Along Strike and to a Vertical Depth of 300 M at Flat Gold Project